Compare Quest Diagnostics Inc (DGX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Recursion Pharmaceuticals Inc — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B). The key difference: Quest Diagnostics Inc is far larger — about 14.5× Recursion Pharmaceuticals Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DGX | RXRX | |
|---|---|---|
Market Cap | $26.21B | $1.81B |
Sector | Health | Health |
52-Week High | $238.50 | $6.79 |
52-Week Low | $173.49 | $2.84 |
Enterprise Value | $31.97B | $1.33B |
Dividend Yield | 1.45% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
